Dry powder inhalant capable of preventing mycobacterium tuberculosis from transmitting through respiratory tract

Abstract

The invention relates to a dry powder inhaler capable of preventing respiratory transmission of Mycobacterium tuberculosis, which can effectively solve the drug problem of preventing and treating tuberculosis infection by Mycobacterium tuberculosis through the respiratory tract. %, rifampicin sustained-release microspheres 19.9-90%, glidant 0.1-5%, first mix isoniazid sustained-release microspheres, rifampicin sustained-release microspheres, and glidants together, Packed in gelatin, plastic capsules or aluminum-plastic blisters, or packaged in a multi-dose dry powder inhalation device in the form of a reservoir; the composition of the present invention is scientific, reasonable, easy to manufacture, good in use effect, and beneficial to powder The body enters the alveoli, and the drug is delivered to the alveoli to be absorbed. It is effectively used to kill and inhibit the Mycobacterium tuberculosis in the trachea, bronchi and alveolar secretions in the respiratory tract, and reduce the number of droplets with floating ability that tuberculosis patients exclude into the surrounding environment. To block the spread of Mycobacterium tuberculosis in the public environment is of great significance to the prevention of tuberculosis.

Description

technical field [0001] The invention relates to medicine, in particular to a dry powder inhaler capable of preventing respiratory transmission of Mycobacterium tuberculosis. Background technique [0002] The transmission routes of tuberculosis include the respiratory tract, digestive tract, skin and uterus, among which the respiratory tract is the main route for mass transmission of Mycobacterium tuberculosis. In 1934, Well proposed that the droplet nuclei (sputum) expelled by the cough of tuberculosis patients contained Mycobacterium tuberculosis, and the droplets could cause tuberculosis infection when they entered the respiratory tract of healthy people. Mycobacterium tuberculosis in droplets (sputum) has a strong ability to survive. In 1969, Loudon's research results showed that 46.7-55.8% of Mycobacterium tuberculosis suspended in the air can still survive after 6 hours and have infection. Ability, when a person sneezes, 10,000 to 40,000 droplets can be sprayed out at ...

AI Technical Summary

Problems solved by technology

At the same time, in order to prevent missed doses and wrong doses in clinical practice, the WHO advocates the use of isoniazid and rifampicin as compound preparations. However, due to the structural problems of the two drugs, isoniazid often causes chemical degradation of rifampicin. Reduce biological activity (Wang Xipei, Wang Siling, etc., Chinese Journal of Pharmacy, 2009), so how to solve the incompatibility of isoniazid and rifampin in the compound preparation of the two is of great significance

[0005] In order to block the transmission of Mycobacterium tuberculosis through the respiratory tract, some scholars made gentamicin, which is difficult to absorb in the lungs, into an aerosol for nasal administration. Kill Mycobacterium tuberculosis in the trachea, bronchi and alveoli (Chad J. Roy et al., Antimicrobial Agents and Chemotherapy, 2010, p. 883–886), but due to the single-drug treatment, it is easy to induce drug resistance of Mycobacterium tuberculosis. Tuberculosis caused by Mycobacterium tuberculosis is obviously disadvantageous

There are also scholars who make capreomycin, which is difficult to absorb in the lungs, into powder aerosols to block the transmission of Mycobacterium tuberculosis through the respiratory tract (Shumaila N. M. Hani et al., Frontiers in Cellular and Infection Microbiol ogy, 2012, 1-11 ), but also derived from the treatment of a single drug, it is easy to induce drug resistance of Mycobacterium tuberculosis, which is obviously unfavorable to tuberculosis caused by Mycobacterium tuberculosis

Images